PE20211698A1 - Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp - Google Patents
Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrpInfo
- Publication number
- PE20211698A1 PE20211698A1 PE2021000700A PE2021000700A PE20211698A1 PE 20211698 A1 PE20211698 A1 PE 20211698A1 PE 2021000700 A PE2021000700 A PE 2021000700A PE 2021000700 A PE2021000700 A PE 2021000700A PE 20211698 A1 PE20211698 A1 PE 20211698A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- activity
- treatment
- nlrp
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Esta referido a compuestos de Formula AA, en donde: A es heteroarilo de 5 a 10 miembros o un C6-C10 arilo; B es un anillo heteroaromatico de 6 miembros; R1 y R2 son alquilo, haloalquilo, alcoxi, entre otros; R3 es H, CN, OH, entre otros; R7 es alquilo, haloalquilo, alcoxi, entre otros; R8 es H, alquilo, alquenilo, cicloalquilo, entre otros; m es 0, 1, o 2; n es 0, 1, o 2; o es 1 o 2; y, p es 0, 1, 2 o 3. Estos compuestos se emplean en el tratamiento de enfermedades relacionadas con una disminucion o un aumento de la actividad de NLRP3, como en el caso de enfermedades inflamatorias o autoinmunitarias.
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862760209P | 2018-11-13 | 2018-11-13 | |
US201862760248P | 2018-11-13 | 2018-11-13 | |
US201862760244P | 2018-11-13 | 2018-11-13 | |
US201862768811P | 2018-11-16 | 2018-11-16 | |
US201862769165P | 2018-11-19 | 2018-11-19 | |
US201862769151P | 2018-11-19 | 2018-11-19 | |
US201962795919P | 2019-01-23 | 2019-01-23 | |
US201962796361P | 2019-01-24 | 2019-01-24 | |
US201962796356P | 2019-01-24 | 2019-01-24 | |
US201962836575P | 2019-04-19 | 2019-04-19 | |
US201962836577P | 2019-04-19 | 2019-04-19 | |
US201962836585P | 2019-04-19 | 2019-04-19 | |
US201962895595P | 2019-09-04 | 2019-09-04 | |
PCT/US2019/060770 WO2020102096A1 (en) | 2018-11-13 | 2019-11-11 | Compounds and compositions for treating conditions associated with nlrp activity |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211698A1 true PE20211698A1 (es) | 2021-09-01 |
Family
ID=68841175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000700A PE20211698A1 (es) | 2018-11-13 | 2019-11-11 | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
Country Status (20)
Country | Link |
---|---|
US (1) | US20230031406A1 (es) |
EP (1) | EP3880660A1 (es) |
JP (2) | JP2022507065A (es) |
KR (1) | KR20210096123A (es) |
CN (1) | CN113166065A (es) |
AU (1) | AU2019379109B2 (es) |
BR (1) | BR112021008969A2 (es) |
CA (1) | CA3114918A1 (es) |
CL (1) | CL2021001228A1 (es) |
CO (1) | CO2021006075A2 (es) |
CR (1) | CR20210235A (es) |
EC (2) | ECSP21033236A (es) |
IL (1) | IL283042B1 (es) |
JO (1) | JOP20210105A1 (es) |
MA (1) | MA54229A (es) |
MX (1) | MX2021005529A (es) |
PE (1) | PE20211698A1 (es) |
SG (1) | SG11202103405TA (es) |
TW (1) | TW202031647A (es) |
WO (1) | WO2020102096A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11370776B2 (en) * | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
EP3668842A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
CA3071150A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
WO2019092170A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
CN112851607A (zh) * | 2019-11-12 | 2021-05-28 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
CN115461120A (zh) * | 2020-01-22 | 2022-12-09 | 豪夫迈·罗氏有限公司 | 作为nlrp3调节剂的磺酰亚胺酰胺化合物 |
WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
TW202246230A (zh) * | 2021-05-10 | 2022-12-01 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
CN116917282A (zh) * | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
CN114989058B (zh) * | 2022-06-02 | 2024-04-16 | 中国科学院成都生物研究所 | 一种手性氯代砜亚胺类化合物及其衍生物的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA47440B1 (fr) * | 2015-02-16 | 2021-08-31 | The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv | Sulfonylurées, composés apparentés, et leur utilisation |
WO2017184623A1 (en) * | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
CN117143042A (zh) * | 2017-07-24 | 2023-12-01 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
-
2019
- 2019-11-11 AU AU2019379109A patent/AU2019379109B2/en active Active
- 2019-11-11 BR BR112021008969-1A patent/BR112021008969A2/pt unknown
- 2019-11-11 JO JOP/2021/0105A patent/JOP20210105A1/ar unknown
- 2019-11-11 JP JP2021525223A patent/JP2022507065A/ja active Pending
- 2019-11-11 US US17/292,881 patent/US20230031406A1/en active Pending
- 2019-11-11 CR CR20210235A patent/CR20210235A/es unknown
- 2019-11-11 WO PCT/US2019/060770 patent/WO2020102096A1/en active Application Filing
- 2019-11-11 CN CN201980074397.XA patent/CN113166065A/zh active Pending
- 2019-11-11 PE PE2021000700A patent/PE20211698A1/es unknown
- 2019-11-11 EP EP19817831.1A patent/EP3880660A1/en active Pending
- 2019-11-11 KR KR1020217017180A patent/KR20210096123A/ko unknown
- 2019-11-11 MA MA054229A patent/MA54229A/fr unknown
- 2019-11-11 MX MX2021005529A patent/MX2021005529A/es unknown
- 2019-11-11 IL IL283042A patent/IL283042B1/en unknown
- 2019-11-11 CA CA3114918A patent/CA3114918A1/en active Pending
- 2019-11-11 SG SG11202103405TA patent/SG11202103405TA/en unknown
- 2019-11-13 TW TW108141175A patent/TW202031647A/zh unknown
-
2021
- 2021-05-10 CO CONC2021/0006075A patent/CO2021006075A2/es unknown
- 2021-05-11 CL CL2021001228A patent/CL2021001228A1/es unknown
- 2021-05-11 EC ECSENADI202133236A patent/ECSP21033236A/es unknown
-
2024
- 2024-06-05 JP JP2024091521A patent/JP2024113083A/ja active Pending
- 2024-06-07 EC ECSENADI202444340A patent/ECSP24044340A/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202103405TA (en) | 2021-05-28 |
AU2019379109B2 (en) | 2022-07-07 |
ECSP24044340A (es) | 2024-07-31 |
JP2022507065A (ja) | 2022-01-18 |
CN113166065A (zh) | 2021-07-23 |
MX2021005529A (es) | 2021-06-18 |
US20230031406A1 (en) | 2023-02-02 |
AU2019379109A1 (en) | 2021-05-06 |
JOP20210105A1 (ar) | 2023-01-30 |
ECSP21033236A (es) | 2021-06-30 |
CL2021001228A1 (es) | 2021-12-31 |
IL283042B1 (en) | 2024-08-01 |
CR20210235A (es) | 2021-06-30 |
WO2020102096A1 (en) | 2020-05-22 |
TW202031647A (zh) | 2020-09-01 |
EP3880660A1 (en) | 2021-09-22 |
JP2024113083A (ja) | 2024-08-21 |
MA54229A (fr) | 2022-02-16 |
KR20210096123A (ko) | 2021-08-04 |
BR112021008969A2 (pt) | 2021-08-03 |
CA3114918A1 (en) | 2020-05-22 |
IL283042A (en) | 2021-06-30 |
CO2021006075A2 (es) | 2021-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211698A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
DOP2022000117A (es) | Inhibidores de kras g12c | |
CU20160097A7 (es) | Compuestos de imidazopirazina como inhibidores de syk | |
PE20190518A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
UY37007A (es) | Compuestos derivados de purinas, estimuladores de genes de interferón | |
UY37461A (es) | 1,2,4 – triazolonas 2,4,5 trisustituida | |
PE20211584A1 (es) | Compuestos antagonistas de pcsk9 | |
UY35991A (es) | Bencimidazol-2-aminas como inhibidores de midh1 | |
PE20160122A1 (es) | Compuestos nobles y composiciones para la inhibicion de fasn | |
PE20142098A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
CU20190086A7 (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados útiles como inhibidores de lats | |
PE20150400A1 (es) | Benzamidas n-sustituidas y su uso en el tratamiento del dolor | |
PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
CY1125004T1 (el) | Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας | |
PE20211782A1 (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
UY36747A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen | |
UY36207A (es) | Inhibidores de la syk | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
EA201591491A1 (ru) | Соединения тетрагидропирролотиазина | |
UY36749A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen | |
UY36702A (es) | Piridinas sustituidas y métodos de uso | |
CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
PE20181357A1 (es) | Agentes inductores de apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes | |
UY35293A (es) | Isotiazoles sustituidos con amino |